← Back to Clinical Trials
Recruiting NCT05644327

NCT05644327 Exercise to Improve Sleep in Parkinson's Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05644327
Status Recruiting
Phase
Sponsor McGill University
Condition Parkinson Disease
Study Type INTERVENTIONAL
Enrollment 150 participants
Start Date 2021-09-01
Primary Completion 2027-12-30

Eligibility & Interventions

Sex All sexes
Min Age 40 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Cardiovascular training (CT)Resistance training (RT)Multimodal training (MT)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 150 participants in total. It began in 2021-09-01 with a primary completion date of 2027-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study will investigate the impact of three common exercise modalities, cardiovascular, resistance, and multimodal (i.e., a combination of the previous two) training, on sleep quality and architecture in persons with Parkinson's disease (PD). Furthermore, the project will investigate whether the potential positive exercise-induced changes in sleep are associated with improvements in different quality of life (QoL)-related aspects. Participants will perform either cardiovascular training (CT), resistance training (RT), multimodal training (MT), or will be allocated to a control condition (i.e., waiting list - CON) for 12 weeks. Training will be performed three times/week. The assessments will be conducted at baseline, post-intervention, and follow-up (i.e. 8 weeks after the intervention) by assessors blinded to the participants' group allocation.

Eligibility Criteria

Inclusion Criteria: * Persons with mild-moderate idiopathic Parkinson's Disease (Modified Hoehn \& Yahr Scale stages 0.5-3.5); * On a stable dosage of medication during the previous month; * Having poor sleep quality defined as a score \> 15 in the PDSS-2 and/or reporting subjective sleep complaints affecting their sleep quality; Exclusion Criteria: * Having atypical parkinsonism, dementia, stroke, or any other neurological condition; * Presenting severe untreated obstructive sleep apnea (OSA); * Having a Montreal Cognitive Assessment (MoCA) score \<18 * Having a Beck Depression Inventory score \>31; * Having absolute contraindications to exercise; * Having severe osteoporosis; * Participating in an exercise or drug trial during the period of the study; * Exceeding the physical activity levels recommended for the general population (≥150 minutes/week of moderate-intensity or ≥75 minutes/week of vigorous-intensity cardiovascular activity) and/or strengthening activities ≥2 days/week.

Contact & Investigator

Central Contact

Marc Roig, Ph.D.

✉ marc.roigpull@mcgill.ca

📞 514-398-4400

Principal Investigator

Marc Roig, Ph.D.

PRINCIPAL INVESTIGATOR

McGill University

Frequently Asked Questions

Who can join the NCT05644327 clinical trial?

This trial is open to participants of all sexes, aged 40 Years or older, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05644327 currently recruiting?

Yes, NCT05644327 is actively recruiting participants. Contact the research team at marc.roigpull@mcgill.ca for enrollment information.

Where is the NCT05644327 trial being conducted?

This trial is being conducted at Laval, Canada, Montreal, Canada, Montreal, Canada.

Who is sponsoring the NCT05644327 clinical trial?

NCT05644327 is sponsored by McGill University. The principal investigator is Marc Roig, Ph.D. at McGill University. The trial plans to enroll 150 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology